FIGURE 1 CALGB (Cancer and Leukemia Group B) 9221: Median time to transformation to acute myeloid leukemia or death in patients with myelodysplastic syndrome treated with azacitidine or given best supportive care
From the following article:
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
Lewis R Silverman and Ghulam J Mufti
BACK TO ARTICLE
Figure 1. CALGB (Cancer and Leukemia Group B) 9221: Median time to transformation to acute myeloid leukemia or death in patients with myelodysplastic syndrome treated with azacitidine or given best supportive care
Measured from entry on study to the time of first event, either transformation to acute myeloid leukemia or death, and estimated according to the Kaplan–Meier method. Adapted from Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429–2440. Reprinted with permission from the American Society of Clinical Oncology.
